A randomised, double blind, placebo controlled, crossover trial of the adjuvant properties of imipramine for the overactive bladder

Not Applicable

Completed

• Conditions: Overactive bladder symptoms; Urological and Genital Diseases

• Registration Number: ISRCTN31004502
• Lead Sponsor: The Whittington Hospital NHS Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-02-20
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Age >= 18 years
2. Able to consent
3. Suffering from overactive bladder symptoms
4. Taking antimuscarinic treatment for detrusor overactivity

Exclusion Criteria

1. Unable to consent
2. Pregnant
3. Breast feeding
4. Recent myocardial infarction
5. History of psychiatric illness
6. Taking monoamine oxidase inhibitors
7. <18 years

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rgency score questionnaire (Al Buheissi S, et al., 2008), carried out after 1 week of run-in period and at 2, 4, 6, 8, 10 and 12 weeks.

Secondary Outcome Measures

Name	Time	Method
The following will be assessed after 1 week of run-in period and at 6 and 12 weeks:<br>1. 24 hour urinary frequency <br>2. Daily urinary Incontinence records <br>3. Patient preference for treatment <br>4. Incontinence Quality of Life questionnaire (I-QOL) score<br>5. Record of side effects